Physician profile

Roseann Maikis

Obstetrics & Gynecology · Nashville, TN

NPI 1811990971

$219.48

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$35.47

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Avion Pharmaceuticals $52.56 2019-2020
Intuitive Surgical, INC. $32.76 2019
Coopersurgical, INC. $27.30 2019
Olympus America INC. $20.57 2019
Hologic Sales and Service, LLC $17.95 2023 Aptima
Pfizer INC. $17.52 2023
Myovant Sciences INC. $16.35 2021
Duchesnay USA Incorporated $13.71 2019
Merck Sharp & Dohme LLC $13.46 2019
Bolder Surgical LLC $7.30 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Roseann Maikis

$219.48

in general payments reported 2019-2025

Years
2019-2023
Top company
Avion Pharmaceuticals

https://glasscript.com/doctor/309114/roseann-maikis

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.